Disrupting certain nerves in the kidneys can safely and effectively lower blood pressure in patients with chronic kidney disease (CKD) and hypertension, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings indicate that the procedure might improve CKD patients’ heart health.
Overactivity of neurons in the sympathetic - or fight or flight - nervous system is very common in patients with CKD. It not only contributes to high blood pressure and heart problems in these patients, but also to worsening of their kidney disease.
A minimally invasive procedure called renal denervation - which uses radiofrequency waves to disrupt the overactive sympathetic nerves running along the arteries in the kidneys—can lower blood pressure in individuals with hypertension and normal kidney function. Dagmara Hering, MD, Markus Schlaich, MD (Baker IDI Heart & Diabetes Institute, in Melbourne, Australia) and their colleagues looked to see if the procedure can also safely help CKD patients with hypertension.
The investigators performed renal denervation in 15 patients with hypertension and CKD. Normal blood pressure in the general population is 120/80 mmHg. Patients’ average level at the start of the study was 174/91 mmHg despite taking numerous antihypertensive drugs. Patients’ blood pressure readings dropped considerably at one, three, six, and 12 months after the procedure (-34/-14, -25/-11, -32/-15, and -33/-19 mmHg, respectively). Renal denervation did not worsen patients’ kidney function, indicating that it is safe even when CKD is present.
“These initial findings now open up an entirely new approach to better control blood pressure in CKD and potentially slow down progression of CKD and reduce cardiovascular risk in these patients. said Dr. Schlaich.
Approximately 60 million people globally have CKD. Heart disease is the leading cause of death in these individuals.
Study co-authors include Felix Mahfoud, MD, Antony Walton, MD, Henry Krum, MBBS, PhD, Gavin W Lambert, PhD, Elisabeth Lambert, PhD, Paul A Sobotka, MD, Michael Böhm, MD, Bodo Cremers, MD, Murray Esler, MBBS, PhD.
Disclosures: This study was funded in part by grants from the National Health and Research Council of Australia (NHMRC) and the Victorian Government’s Operational Infrastructure Support Program. Professor Schlaich, Prof Esler, Dr E Lambert, and Dr G Lambert are supported by career fellowships from the NHMRC. Dr Dagmara Hering is currently supported by Research Fellowship from the Foundation for Polish Science KOLUMB/2010-1. Dr Felix Mahfoud is supported by the Deutsche Hochdruckliga. Dres Schlaich, Mahfoud, Walton, Krum, Boehm, Esler are principal investigators in studies sponsored by Medtronic, the company that manufactures the renal deneravtion device and have received consultancy/lecture fees from Medtronic.
The article, entitled “Renal Denervation in Moderate to Severe CKD,” will appear online at http://jasn.asnjournals.org/ on May 17, 2012 2012, doi: 10.1681/ASN.2011111062.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with more than 13,500 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.
A minimally invasive procedure called renal denervation, which disrupts certain nerves in the kidneys, lowers blood pressure in patients with chronic kidney disease and hypertension.
The procedure may help protect the kidneys and reduce heart risks in patients with chronic kidney disease.
60 million people globally have chronic kidney disease.
American Society of Nephrology